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Abstract: Preoperative and intraoperative lymph node (LN) staging
is of paramount importance for patients with non-small cell lung
cancer. The Council of the European Society of Thoracic Surgery
took the initiative to organize workshops on intraoperative and
preoperative mediastinal LN staging. This resulted in specific guide-
lines. Relevant peer-reviewed publications on these subjects, the
experience of the participants, and the opinion of the European
Society of Thoracic Surgery members contributing online were used
to reach a consensus. For primary staging, mediastinoscopy remains
the gold standard for the superior mediastinal LNs. Invasive proce-
dures can be omitted in patients with peripheral tumors and negative
mediastinal and hilar nodes on positron emission tomography scan.
Positron emission tomography-positive mediastinal findings should
always be cytohistologically confirmed. New minimally invasive
techniques that provide cytohistological diagnosis became available.
Their specificity is high, but the negative predictive value is low. If
they yield negative results, an invasive surgical technique remains
indicated. For restaging, invasive techniques providing cytohisto-
logical information are advisable. Systematic nodal dissection is
recommended in all cases to ensure complete resection. Lobe-
specific systematic nodal dissection is acceptable for peripheral
squamous T1 tumors if hilar and interlobar nodes are negative on
frozen section studies. The report from the pathologist should
describe the number of LNs removed and studied, the overall
number of metastatic LNs in each station, and the status of the LN
capsule. We hope that the adherence to these guidelines will stan-
dardize and improve preoperative and intraoperative LN staging and
pathologic evaluation of non-small cell lung cancer.
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(J Thorac Oncol. 2007;2: 357–361)
Patients with pathologically diagnosed involved mediasti-nal lymph nodes (LNs) have a dismal outcome when
treated with surgery or radiotherapy alone. To improve the
outcome for these patients, the concept of multimodality
treatment has been introduced. Mainly patients with medias-
tinal down-staging will benefit from resection.
Therefore, accurate preoperative staging and restaging
of mediastinal LNs after induction therapy is of paramount
importance. Over the last years, different techniques of me-
diastinal staging have become available. They vary in accu-
racy and procedure-related morbidity.
However, clinical staging is not perfect. At thoracot-
omy, the surgeon has an important role in the assessment of
local tumor spread and nodal involvement. The assessment of
mediastinal LNs during surgery is even more controversial
and variable than the preoperative LN staging. In the litera-
ture, many names of procedures are used, but they are not
well described and defined.
The Council of the European Society of Thoracic Sur-
gery (ESTS) took the initiative to organize two workshops on
intraoperative mediastinal LN staging and preoperative me-
diastinal LN staging. Relevant peer-reviewed publications on
these subjects, the experience of the participants, and the
opinion of the ESTS members contributing online were used
to reach a consensus.
ESTS GUIDELINES ON PREOPERATIVE LN
STAGING IN NSCLC
A Distinction between Pretreatment and Posttreatment
Mediastinal LN Staging Is Made.
PREOPERATIVE (PRETREATMENT)
MEDIASTINAL LN STAGING
Although computed tomographic (CT) scan is very
accurate in detecting LN enlargement, the clinical relevance
of LN enlargement for staging is poor because small nodes
may contain metastases in up to 20% and large nodes may be
benign. In a review, pooled data yielded a sensitivity of 57%,
a specificity of 82%, a positive predictive value of 56%, and
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a negative predictive value (NPV) of 83%, with a marked
heterogeneity among individual studies.1
This performance is insufficient for clinical decision
making. The involvement of mediastinal LNs in patients with
small LNs on CT scan is very much dependent on the
histological type and T-stage of the tumor.2
Positron emission tomography with 18F-fluoro-2-deoxy-
D-glucose is superior to CT for mediastinal LN staging in
potentially operable NSCLC.
Sensitivities and NPVs were comparable for PET com-
pared with mediastinoscopy.1 Because of the high NPV of
PET scan, invasive staging procedures can generally be
omitted in patients with clinical stage I NSCLC with negative
mediastinal PET images. This implementation should be
dealt with caution in the case of patients with central tumors,
hilar N1-disease on PET scan, bronchio-alveolar cell carci-
noma,3 and large mediastinal PET-negative LNs (16 mm)
on CT scan.4 The positive predictive value of PET scan is
only 79%. In the case of positive mediastinal PET, tissue
confirmation is still needed to confirm LN metastasis.
Mediastinoscopy remains the gold standard for inva-
sive staging of tumors for patients with potentially opera-
ble lung cancer. Different forms of mediastinoscopy have
been described. Cervical mediastinoscopy is the most
commonly used. The sensitivity of cervical mediastinos-
copy varies between 72% and 89%, with an average of
81% and a NPV of 91%.1
There is no internationally accepted recommendation
on how many LN stations should be examined at cervical
mediastinoscopy. There are no data indicating that more
systematic sampling at mediastinoscopy makes a difference, but
extrapolation from data on occasional and systematic sampling
at thoracotomy suggests that this may be important.5
The ESTS working group recommends systematically
exploring and always performing a biopsy of the right and left
lower paratracheal nodes and the subcarinal nodes. Addition-
ally, if present, the upper paratracheal LNs should be sampled
and biopsied.
More recently, mediastinoscopy is performed by the
use of a videomediastinoscope.6 This improves visualization
of the operative field (Figure 1) and may lead to a higher
accuracy in staging and a better standardization of the tech-
nique. The learning curve of video-assisted mediastinoscopy
is short compared with conventional mediastinoscopy.
Endoscopic techniques are minimally invasive ap-
proaches that provide histological or cytological confirmation
of nodal tumor involvement. A sensitivity of 76% and a
false-negative rate of 29% were reported for conventional
transbronchial needle aspiration (TBNA) in clinical N2 dis-
ease.1 This high false-negative rate compromises the use of
conventional TBNA for routine mediastinal LN staging; how-
ever, it can be used as a preliminary diagnostic test comple-
mented in negative cases with surgical staging. The sensitiv-
ity of TBNA critically depends on the prevalence of
mediastinal LN metastases. In populations with a lower
prevalence of mediastinal metastases, the sensitivity of
TBNA is much lower than reported in recent lung cancer
guidelines.7 The accuracy can be improved by guidance with
endoscopic ultrasonography (EBUS-TBNA). Esophageal ul-
trasound-guided fine needle aspiration (EUS-FNA) is mainly
suitable for the assessment of LNs in the posterior part of
levels 4L, 5, and 7 and in the inferior mediastinum at levels
8 and 9 as described on the Mountain-Dresler map.8
ESTS GUIDELINES FOR BASELINE
MEDIASTINAL LN STAGING
Chest CT is still the basic imaging modality in lung
cancer. However, CT scan of the chest is not accurate
enough for mediastinal LN staging. When only CT scan is
available, invasive staging is advised for every patient
except for a T1 squamous cell tumor with no or small LNs
on CT scan.
Invasive staging can be omitted for patients with stage
I NSCLC and negative mediastinal PET images. However, in
the case of central tumors, PET hilar N1 disease, low positron
emission tomography with 18F-fluoro-2-deoxy-D-glucose up-
take of the primary tumor and large LNs on CT (16 mm),
invasive staging remains indicated.
PET-Positive Mediastinal Findings Should Be Histo-
logically or Cytologically Confirmed.
TBNA, EBUS-FNA, EUS-FNA, and transthoracic nee-
dle aspiration are minimally invasive techniques that provide
FIGURE 1. Improved visualization by cervical videomediastinoscopy.
De Leyn et al. Journal of Thoracic Oncology • Volume 2, Number 4, April 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer358
cytohistological diagnosis. They can be complementary to
surgical invasive staging techniques. Their specificity is high,
but their NPV is low. For this reason, an invasive surgical
technique remains indicated if they yield negative results.
However, if fine needle aspiration is positive, this result may
be valid as proof of N2 or N3 disease.
Cervical mediastinoscopy provides the advantage that a
more complete mapping of mediastinal LNs can be per-
formed. Ideally, all accessible LN stations should be explored
and biopsied. At least one ipsilateral, one contralateral and
the subcarinal LNs should be biopsied.
The proposed algorithm for primary mediastinal stag-
ing is detailed in Figure 2.
MEDIASTINAL LN RESTAGING AFTER
INDUCTION THERAPY
The mediastinum can be restaged by the same tech-
niques as applied in primary staging.
For mediastinal restaging after induction chemother-
apy, the PET scan is more accurate than the CT scan but is
clearly not as accurate as in untreated patients. In most
FIGURE 2. Proposed algorithm for mediastinal staging.
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studies, the sensitivity is reported to be 50% to 60% with a
good specificity of 85% to 90%. In a high proportion of
patients, the PET scan is false negative regarding mediastinal
nodal involvement after induction therapy. In a prospective
study,9 the use of PET-CT fusion images significantly in-
creased accuracy through better localization of focal, even
moderate, positron emission tomography with 18F-fluoro-2-
deoxy-D-glucose update in mediastinal LNs or other vascu-
lar-mediastinal structures.
Repeat mediastinoscopy, although technically more
difficult than the first procedure, offers the advantage of
providing histological evidence of response after induction
therapy. Only a few centers have reported their experience
with repeat mediastinoscopy. Some series reported sensitiv-
ities of 70%.10–12 A prospective study evaluated the accuracy
of re-mediastinoscopy and PET-CT in restaging the medias-
tinum.9 The sensitivity to detect residual positive mediastinal
LNs was only 29%. Although there is no clear answer to
explain the different results, the authors suggested that the
degree of adhesions and mediastinal fibrosis is mainly sec-
ondary to pre-induction mediastinoscopy, rather than to the
induction treatment itself.
A study from The Netherlands reported results from 19
patients with proven N2 disease that were restaged by EUS
after induction chemotherapy.13 Diagnostic accuracy in this
study was 83%.
ESTS GUIDELINES FOR RESTAGING
At the present time, CT, PET, or PET-CT is not
accurate enough to make final further therapeutic decisions.
An invasive technique providing cytohistological infor-
mation is recommended. For restaging, endoscopic tech-
niques or surgical invasive techniques can be used. If they
yield a positive result, non-surgical treatment seems to be
indicated for most patients. The choice of invasive techniques
may be dependent on the availability of the technique and
expertise of the center.
ESTS GUIDELINES ON INTRAOPERATIVE LN
STAGING IN NSCLC
Mapping of LNs to the Appropriate LN Station
In 1997, the latest revised International Staging System
was released.8 The ESTS working group identified five areas
in which the demarcation among the LN stations was either
arbitrary or not identifiable at mediastinoscopy or intraoper-
ative staging. The limitations of the present nodal charts will
be addressed in a new International Nodal Charts that will be
included in the next revision of the UICC Staging System to
be implemented in January 2009.
Moreover, the working group found that the impor-
tance of the number of investigated versus involved nodes
and LN stations has not been addressed in the current
staging systems.
Rationale for Intraoperative LN Assessment
There are data that clearly show that systematic sam-
pling or nodal dissection improves intraoperative staging in
contrast to selected LN sampling, especially regarding the
detection of multi-level N2 disease. The rate of unforeseen
N2 disease will also depend on the methods applied for
preoperative staging. There is controversy whether extending
the LN dissection influences survival or recurrence rate of the
disease. A removal of at least six LNs (UICC) from hilar and
mediastinal stations is recommended to define nodal staging
accurately and to determine pN0 status.
ESTS Definitions for Intraoperative LN
Assessment.
The ESTS provided clear definitions for the following
procedures: selected LN biopsy, sampling, systematic sam-
pling, systematic nodal dissection, lobe-specific systematic
LN dissection, and extended LN dissection.5
ESTS Recommendation of Intraoperative LN
Assessment
For complete resection of NSCLC, a systematic nodal
dissection is recommended in all cases.14,15 All the medias-
tinal tissue containing the LNs is dissected and removed
systematically within anatomical landmarks. It is important
that the nodal stations are excised and put into different vials
with separate labeling. The highest removed mediastinal
node should be identified. Lymph node assessment is
performed before lung resection. In some cases, especially
after induction treatment, nodal information may change
surgical procedure.
For peripheral squamous cell T1 tumors, a more selec-
tive nodal dissection depending on the lobar location of the
primary tumor (lobe specific systematic nodal dissection) is
acceptable. The probability of unforeseen N2 disease is very
low (less than 5%) for these patients.2,3
In high-risk patients, intraoperative LN assessment can
be reduced, but if the patient can tolerate a lobectomy,
systematic nodal dissection should be performed.
ESTS Recommendations on Histopathological
Evaluation of the Removed LNs
The ESTS working group gives recommendations on
how LNs should be examined in resected specimens of
patients with NSCLC.5
The report from the pathologist should describe the
number of LNs removed and studied, the overall number of
metastatic LNs in each station, and the status of the LN
capsule.
Full text of the guidelines are available.5,16
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